GlobeNewswire by notified

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder

Share

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to coverPhase 3 development ofmavoglurant in cocaineuse disorder

Agreement follows STALICLA’srecent in-licencing of mavoglurant from Novartis

Geneva, Switzerland8March2023, STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). The agreement covers the clinical development program of mavoglurant to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

NIDA is the lead federal agency supporting scientific research on drug use and addiction to improve individual and public health. Under the terms of the CRADA, NIDA will cover under its own account the Phase 3 trial for mavoglurant, which is slated to enrol up to 330 patients. The investigational product was in-licensed by STALICLA from Novartis in return for undisclosed late-stage milestone payments and royalties, in an agreement announced in January this year. Novartis has also taken an equity stake in STALICLA.

Lynn Durham, STALICLA’s Founder & CEO, commented: “Our CRADA with NIDA allows us to enter into late stage development and is a testament to STALICLA’s commitment to bring new treatments to patients suffering from neuropsychiatric and neurodevelopmental disorders. It is also a validation of mavoglurant’s potential in treating patients with substance-abuse disorders. We have onboarded an exceptional partner in NIDA and we are excited about working together to accelerate mavoglurant towards a new drug application.”

About mavoglurant

Mavoglurant is the most clinically advanced selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist. mGluR5 has been tied to mood disorders, addiction as well as rare and common forms of Autism. In clinical Phase 2 studies, mavoglurant has been shown to induce abstinence in cocaine use disorder patients through inhibition of mGluR5, with no evidence of withdrawal liability.

About STALICLA

STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.

STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.

With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.

The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.

STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform.

For further information, please visit: https://stalicla.com/

Contacts

STALICLA SA
Lynn Durham, CEO
Lynn.durham@stalicla.com
Media enquiries
Consilium Strategic Communications
stalicla@consilium-comms.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vow ASA: Full year and second half of 2023 results28.2.2024 23:11:51 CET | Press release

Oslo, 28 February 2024: Vow ASA (OSE: VOW) revenues for the full year 2023 were NOK 918.5 million, a 17 per cent increase from the year before. EBITDA before non-recurring items was negative NOK 23.4 million for the full year. In addition, the company recorded non-recurring items of negative NOK 31.3 million, mainly related to non-cash balance sheet clean-up in contract accruals. This resulted in a negative EBITDA for the year of NOK 54.7 million versus a positive NOK 85.5 million in 2022. “The year 2023 was a year of high activity and revenue. A large number of projects were successfully delivered. Activity in aftersales was increasing. We also secured important new contracts and moved into position for new projects in new industry verticals,” said Henrik Badin, CEO of Vow ASA. At the end of 2023, the order backlog was NOK 1 034 million and another NOK 921 million in options. The backlog and options are providing visibility for revenues and good margins well into 2025/26. “We have als

European Energy A/S: Notice to convene ordinary general meeting28.2.2024 23:08:42 CET | Press release

Company announcement 7/2024 (28.02.2024) The Board of Directors of the Company hereby convenes an ordinary general meeting of the Company, to be held on: Thursday 14 March 2024 at 09:30 CET at the address of the Company, Gyngemose Parkvej 50, 2860 Søborg, Denmark and electronically on Teams Agenda: Election of Chair of the Annual General Meeting.Report on the activities of the Company.Presentation of the annual report with the auditors’ report for approval and discharge of the Board of Directors and the Executive Board.Resolution on the appropriation of profit or treatment of loss according to the approved annual report.Election of members to the Board of Directors.Decision regarding remuneration to the Board of Directors for the financial year 2024. Amendments to the article of association.Election of Auditor(s).AOB. Attachment Notice to convene ordinary general meeting

European Energy A/S: Full-year Financial Report 2023 - Shows resilience and growth in turbulent year28.2.2024 23:00:49 CET | Press release

Company announcement 6/2024 (28.02.2024) European Energy announces its financial report for the full-year 2023. Highlights: Record high EBITDA of EUR 178m represents a 27% increase, achieving our 2023 financial outlook. This result was driven largely by the sale of energy parks and projects, including a revaluation gain from Kassø, partly offset by increasing staff and external expenses due to higher activityRecord Electricity Generation: In 2023, our total renewable energy production reached a record high level of 1,870 GWh or +140% compared to 2022. As power prices in many markets more than halved during 2023, our power sales profit was stable compared to 2022Profitable Power-to-X Projects: Demonstrated through the profitable farm down of the world's largest e-methanol project in Kassø to Mitsui. Another achievement in 2023 was securing over DKK 1bn from Danish green hydrogen price premium tenders, ensuring significant subsidies for the next decade for three new Danish PtX projects.V

Amlan International Forges Strategic Partnership with Grupo Profil as its Newest Latin American Distributor, Amplifying Access to Innovative Gut Health Solutions for Protein Producers28.2.2024 23:00:42 CET | Press release

CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Amlan® International, the animal health division of Oil-Dri® Corporation of America, is excited to announce its partnership with Grupo Profil as the newest distributor for the Latin American region. Known for their dedication to providing natural alternatives and comprehensive solutions in prophylaxis and nutrition to the regional livestock sector, Grupo Profil will now offer Amlan's innovative, natural feed additives to animal health retailers across Guatemala, El Salvador, and Honduras. Amlan will collaborate with Profil to expand its impact on the growing Latin American market. Profil's commitment to delivering advanced, effective solutions to the market perfectly aligns with Amlan's mission to enhance animal health and productivity while reducing reliance on antibiotics and synthetic additives. Through this partnership, Profil will distribute Amlan’s Calibrin®-Z, Calibrin®-A, Varium®, and NeoPrime®, catering to the poultry, swine, aquacult

Havila Kystruten AS: Fourth quarter 2023 accounts28.2.2024 22:24:49 CET | Press release

Summary The company has completed its first quarter with full operation of all four ships. Revenue in the fourth quarter was MNOK 249. Due to late clarification on the delivery of the last two ships, the revenue side is somewhat lower than if the pre-sale had started earlier. The last quarter of 2023 ended with an average fleet occupancy of 60%, an average cabin rate (ACR) of NOK 3,100 and a utilization rate of 1.8 per cabin. Occupancy and average price per cabin are higher than the fourth quarter of 2022, but are somewhat lower than the third quarter due to lower demand in the autumn and winter months. EBITDA was negative by MNOK 33.2 in the fourth quarter and MNOK 179 for the full year. Operating costs amounted to MNOK 283 in the fourth quarter and are mainly ordinary operating costs for operating four ships. Some of the operating costs are related to the number of passengers, while the largest cost items are not significantly affected by occupancy. MNOK 18 relates to extraordinary m

HiddenA line styled icon from Orion Icon Library.Eye